keyword
MENU ▼
Read by QxMD icon Read
search

Subcutaneous immunoglobulin

keyword
https://www.readbyqxmd.com/read/29326423/peripheral-neuropathies-subcutaneous-immunoglobulin-the-future-of-cidp-treatment
#1
Benjamin R Wakerley, Nobuhiro Yuki
No abstract text is available yet for this article.
January 12, 2018: Nature Reviews. Neurology
https://www.readbyqxmd.com/read/29318623/subcutaneous-immunotherapy-with-purified-der-p1-and-2-suppresses-type-2-immunity-in-a-murine-asthma-model
#2
Laura Hesse, Nienke van Ieperen, Corine Habraken, Arjen H Petersen, Silvia Korn, Tim Smilda, Betty Goedewaagen, Marcel H Ruiters, Adrianus C van der Graaf, Martijn C Nawijn
Allergen-specific immunotherapy can induce long-term suppression of allergic symptoms, reduce medication use and prevent exacerbations of allergic rhinitis and asthma. Current treatment is based on crude allergen extracts, which contain immunostimulatory components such as β-glucans, chitins and endotoxin. Use of purified or recombinant allergens might therefore increase efficacy of treatment. Here, we test application of purified natural group 1 and 2 allergens from Dermatophagoides pteronyssinus (Der p) for subcutaneous immunotherapy (SCIT) treatment in a house dust mite (HDM) driven mouse model of allergic asthma...
January 10, 2018: Allergy
https://www.readbyqxmd.com/read/29298756/adct-402-a-pbd-dimer-containing-antibody-drug-conjugate-targeting-cd19-expressing-malignancies
#3
Francesca Zammarchi, Simon Corbett, Lauren Adams, Peter C Tyrer, Konstantinos Kiakos, Narinder Janghra, Teresa Marafioti, Charles E Britten, Carin E G Havenith, Simon Chivers, Francois D'Hooge, David G Williams, Arnaud Tiberghien, Philip W Howard, John A Hartley, Patrick H van Berkel
Human CD19 antigen is a 95-kDa type I membrane glycoprotein in the immunoglobulin superfamily whose expression is limited to the various stages of B-cell development and differentiation and is maintained in the majority of B-cell malignancies, including leukemias and non-Hodgkin lymphomas of B-cell origin. Coupled with its differential and favourable expression profile, CD19 has rapid internalization kinetics and it is not shed into the circulation, making it an ideal target for the development of antibody-drug conjugates (ADCs) to treat B-cell malignancies...
January 3, 2018: Blood
https://www.readbyqxmd.com/read/29298625/initial-romiplostim-dosing-and-time-to-platelet-response-in-patients-with-treatment-refractory-immune-thrombocytopenia
#4
Ryan K DasGupta, Lauren Levine, Tracy Wiczer, Spero Cataland
Background/rationale Romiplostim is a thrombopoietin receptor agonist recommended as a second-line therapy for immune thrombocytopenia. An initial dose of 1 mcg/kg/week subcutaneously with weekly 1 mcg/kg dose escalation is recommended per package labeling. Optimizing romiplostim dosing for hospitalized, corticosteroid- and intravenous immunoglobulin-refractory patients with severe thrombocytopenia secondary to immune thrombocytopenia may be critical for improving platelet responses, reducing the risk of bleeding, and decreasing hospital length of stay...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29280519/subcutaneous-immunoglobulin-for-the-treatment-of-deep-morphoea-in-a-child
#5
M A Yamazaki-Nakashimada, M Saez-de-Ocariz, G Maldonado-Colin, M T García-Romero
Morphoea, also known as localized scleroderma, is a disorder characterized by excessive collagen deposition leading to thickening of the dermis and/or subcutaneous tissues. Intravenous IgG therapy has induced improvement in some fibrotic conditions. The primary indication for subcutaneous IgG (SCIG) is in primary immunodeficiency disorders as replacement therapy; however, recently there has been considerable interest in SCIG as an immunomodulatory agent. We report an 11-year-old girl with deep morphoea who was successfully treated with SCIG...
December 27, 2017: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/29273130/efficacy-and-safety-of-birch-pollen-immunotherapy-for-local-allergic-rhinitis
#6
Andrzej Bożek, Krzysztof Kołodziejczyk, Jerzy Jarząb
BACKGROUND: Local allergic rhinitis (LAR) is a relatively new disease. OBJECTIVE: To ascertain the effects of allergen-specific immunotherapy in LAR. METHODS: A randomized, double-blind, placebo-controlled trial of birch subcutaneous allergen immunotherapy (AIT) for LAR was performed in 28 patients. The therapy was performed for 24 months in 15 patients with AIT and 13 patients given placebo. The primary end point was decrease in symptom medication score (SMS)...
January 2018: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/29245273/a-delayed-diagnosis-of-x-linked-hyper-igm-syndrome-complicated-with-toxoplasmic-encephalitis-in-a-child-a-case-report-and-literature-review
#7
Xiaoliang Liu, Kaiyu Zhou, Dan Yu, Xiaotang Cai, Yimin Hua, Hui Zhou, Chuan Wang
INTRODUCTION: The X-linked hyper-immunoglobulin M syndrome (XHIGM) is an uncommon primary combined immunodeficiency disease caused by CD40L gene mutations. A delayed or missed diagnosis of XHIGM is common and concerning, owing to atypical immunoglobulin profile and phenotype of some patients, low recognition, and limited knowledge of clinicians on XHIGM in some underdeveloped areas. Opportunistic infections are a prominent clinical feature of XHIGM. However, toxoplasma encephalitis occurs sporadically and is extremely rare in patients with XHIGM...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29223720/serum-periostin-is-associated-with-body-mass-index-and-allergic-rhinitis-in-healthy-and-asthmatic-subjects
#8
Hirokazu Kimura, Satoshi Konno, Hironi Makita, Natsuko Taniguchi, Hiroki Kimura, Houman Goudarzi, Kaoruko Shimizu, Masaru Suzuki, Noriharu Shijubo, Katsunori Shigehara, Junya Ono, Kenji Izuhara, Yoichi Minagawa Ito, Masaharu Nishimura
BACKGROUND: Many studies have attempted to clarify the factors associated with serum periostin levels in asthmatic patients. However, these results were based on studies of subjects mainly characterized by high eosinophil counts, which may present as an obstacle for clarification in the identification of other factors associated with serum periostin levels. The aim of this study was to determine the factors associated with serum periostin levels in healthy subjects. We also assessed some factors in asthmatic subjects to confirm their extrapolation for management of asthma...
December 6, 2017: Allergology International: Official Journal of the Japanese Society of Allergology
https://www.readbyqxmd.com/read/29191714/subcutaneous-immunoglobulins-in-patients-with-multiple-myeloma-and-secondary-hypogammaglobulinemia
#9
Angelo Vacca, Carolina Marasco, Assunta Melaccio, Azzurra Sportelli, Ilaria Saltarella, Antonio Solimando, Franco Dammacco, Roberto Ria
Multiple myeloma is commonly associated with a reduction of non-paraprotein immunoglobulins, resulting in a higher risk of infections that represent the leading cause of the patients' death. Therefore, immunoglobulin replacement therapy appears a logical approach. A total number of 46 myeloma patients were enrolled: 24 of them were assigned to receive subcutaneous immunoglobulins, and 22 were controls. The primary endpoint was the evaluation of the annual rate of severe infections in immunoglobulins-receiving patients as compared with those untreated...
November 27, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/29181272/new-insights-in-the-use-of-immunoglobulins-for-the-management-of-immune-deficiency-pid-patients
#10
REVIEW
Gergely Krivan, Stephen Jolles, Eduardo Lopes Granados, Phillipe Paolantonacci, Rabye Ouaja, Ousmane Alfa Cissé, Ewa Bernatowska
Immunoglobulin replacement therapy (IRT) is standard treatment for patients with primary immunodeficiency (PID). Because most of the patients with PID will require long life-time immunoglobulin replacement therapy, the quality of the prescribed products is of utmost importance. The IRT is generally administered either intravenously (abbreviated IVIG), or subcutaneously (abbreviated SCIG). Both routes have been demonstrated to be effective. The preferred route may vary at different times during a given patient's life...
2017: American Journal of Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/29178674/a-retrospective-study-of-clinical-response-predictors-in-subcutaneous-allergen-immunotherapy-with-house-dust-mites-for-allergic-rhinitis
#11
Ji Ho Lee, Su Chin Kim, Hyunna Choi, Chang Gyu Jung, Ga Young Ban, Yoo Seob Shin, Dong Ho Nahm, Hae Sim Park, Young Min Ye
PURPOSE: House dust mites (HDM) are major allergens that cause allergic rhinitis (AR). Allergen-specific subcutaneous immunotherapy (SCIT) has been shown to be clinically beneficial in many clinical trials. Such trials, however, are not reflective of all patient populations. The aim of this study was to describe the efficacy and safety of SCIT in routine clinical practice in Korean adults with AR sensitized to HDM. METHODS: We reviewed medical records of 304 patients with AR treated at an allergy clinic of a tertiary hospital using SCIT with aluminum hydroxide-adsorbed allergen extract targeting HDM alone or with pollens for at least 1 year from 2000 to 2012...
January 2018: Allergy, Asthma & Immunology Research
https://www.readbyqxmd.com/read/29150857/a-randomized-double-blind-placebo-controlled-dose-finding-trial-with-lolium-perenne-peptide-immunotherapy
#12
Ralph Mösges, Elena M Kasche, Esther Raskopf, Jaswinder Singh, Lea Sohlich, Anatoli Astvatsatourov, Kija Shah-Hosseini, Sabine Pirotton, Ludo Haazen, Stephen R Durham, Thierry Legon, Gregor Zadoyan, Mohamed H Shamji
BACKGROUND: A novel subcutaneous allergen immunotherapy formulation (gpASIT+(™) ) containing Lolium perenne peptides (LPP) and having a short up-dosing phase has been developed to treat grass pollen-induced seasonal allergic rhinoconjunctivitis. We investigated peptide immunotherapy containing the hydrolysate from perennial ryegrass allergens for the optimum dose in terms of clinical efficacy, immunogenicity, and safety. METHODS: This prospective, double-blind, placebo-controlled, phase IIb, parallel, four-arm, dose-finding study randomized 198 grass pollen-allergic adults to receive placebo or cumulative doses of 70, 170, or 370 μg LPP...
November 18, 2017: Allergy
https://www.readbyqxmd.com/read/29145505/spontaneous-development-of-epstein-barr-virus-associated-human-lymphomas-in-a-prostate-cancer-xenograft-program
#13
Alberto J Taurozzi, Ramprakash Beekharry, Michelle Wantoch, Marie-Christine Labarthe, Hannah F Walker, Robert I Seed, Matthew Simms, Greta Rodrigues, James Bradford, Geertje van der Horst, Gabri van der Pluijm, Anne T Collins
Prostate cancer research is hampered by the lack of in vivo preclinical models that accurately reflect patient tumour biology and the clinical heterogeneity of human prostate cancer. To overcome these limitations we propagated and characterised a new collection of patient-derived prostate cancer xenografts. Tumour fragments from 147 unsupervised, surgical prostate samples were implanted subcutaneously into immunodeficient Rag2-/-γC-/- mice within 24 hours of surgery. Histologic and molecular characterisation of xenografts was compared with patient characteristics, including androgen-deprivation therapy, and exome sequencing...
2017: PloS One
https://www.readbyqxmd.com/read/29144049/characterization-of-children-with-recurrent-eczema-herpeticum-and-response-to-treatment-with-interferon-gamma
#14
Kavita Darji, Stephanie Frisch, Eric Adjei Boakye, Elaine Siegfried
BACKGROUND/OBJECTIVES: Interferon gamma (IFN-γ) has been used treat severe atopic dermatitis, with equivocal results. Recurrent eczema herpeticum is an underappreciated, therapeutically challenging complication of severe atopic dermatitis. Defects in IFN-γ and other cytokine pathways have been identified in individuals with confirmed eczema herpeticum. This suggests possible benefit from IFN-γ treatment for confirmed eczema herpeticum. The objective of the current study was to evaluate immunologic and microbial parameters and response to IFN-γ treatment in children with confirmed eczema herpeticum...
November 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/29133207/oral-hepatitis-b-vaccine-chitosan-or-glucan-based-delivery-systems-for-efficient-hbsag-immunization-following-subcutaneous-priming
#15
Edna Soares, Sandra Jesus, Olga Borges
The World Health Organization encourages "the development of oral formulations to simplify their transport, storage and administration in poor countries", and to "facilitate an effective immunization program to prevent sexually transmitted hepatitis B". Thus, two distinct and promising delivery systems were developed: recombinant hepatitis B surface antigen (HBsAg) encapsulated into alginate-coated chitosan particles (AlgChiPs) and into glucan particles (GPs) mainly composed of β-1,3-d-glucan. In vitro preliminary studies showed that both could be internalized by peripheral blood mononuclear cells and murine Peyer's patches, an imperative aspect regarding oral immunization...
November 11, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29122523/subcutaneous-immunoglobulin-for-maintenance-treatment-in-chronic-inflammatory-demyelinating-polyneuropathy-path-a-randomised-double-blind-placebo-controlled-phase-3-trial
#16
Ivo N van Schaik, Vera Bril, Nan van Geloven, Hans-Peter Hartung, Richard A Lewis, Gen Sobue, John-Philip Lawo, Michaela Praus, Orell Mielke, Billie L Durn, David R Cornblath, Ingemar S J Merkies
BACKGROUND: Approximately two-thirds of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) need long-term intravenous immunoglobulin. Subcutaneous immunoglobulin (SCIg) is an alternative option for immunoglobulin delivery, but has not previously been investigated in a large trial of CIDP. The PATH study compared relapse rates in patients given SCIg versus placebo. METHODS: Between March 12, 2012, and Sept 20, 2016, we studied patients from 69 neuromuscular centres in North America, Europe, Israel, Australia, and Japan...
November 6, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/29095327/cerebral-venous-sinus-thrombosis-due-to-low-molecular-weight-heparin-induced-thrombocytopenia
#17
Ezequiel Gleichgerrcht, Ming Y Lim, Tanya N Turan
INTRODUCTION: Heparin-induced thrombocytopenia (HIT) is an immune-mediated complication of heparin exposure. A limited number of studies have reported cerebral venous sinus thrombosis (CVST) as the presenting thrombotic event induced by HIT, only one of which occurred with exposure to low-molecular-weight heparin (LMWH), with death as outcome. Here, we present a unique case of LMWH-induced HIT leading to CVST but resulting in good clinical outcome. CASE REPORT: A 52-year-old woman received subcutaneous LMWH for deep vein thrombosis prophylaxis while in rehabilitation following kyphoplasty for spinal fracture related to recent trauma...
November 2017: Neurologist
https://www.readbyqxmd.com/read/29093180/the-fcrn-inhibitor-rozanolixizumab-reduces-human-serum-igg-concentration-a-randomized-phase-1-study
#18
Peter Kiessling, Rocio Lledo-Garcia, Shikiko Watanabe, Grant Langdon, Diep Tran, Muhammad Bari, Louis Christodoulou, Emma Jones, Graham Price, Bryan Smith, Frank Brennan, Ian White, Stephen Jolles
Pathogenic immunoglobulin G (IgG) autoantibodies characterize some human autoimmune diseases; their high concentration and long half-life are dependent on recycling by the neonatal Fc receptor (FcRn). Inhibition of FcRn is an attractive new treatment concept for IgG-mediated autoimmune diseases. Rozanolixizumab (UCB7665; CA170_01519.g57 IgG4P) is an anti-human FcRn monoclonal antibody. In cynomolgus monkeys, rozanolixizumab reduced IgG (maximum 75 to 90% by about day 10), was well tolerated, and did not increase risk of infection...
November 1, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/29090020/long-term-treatment-of-refractory-myasthenia-gravis-with-subcutaneous-immunoglobulin
#19
Edina Kovács, Katalin Dankó, Melinda Nagy-Vince, László Csiba, Judit Boczán
No abstract text is available yet for this article.
November 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/29032329/successful-transdermal-allergen-delivery-and-allergen-specific-immunotherapy-using-biodegradable-microneedle-patches
#20
Ji Hye Kim, Jung U Shin, Seo Hyeong Kim, Ji Yeon Noh, Hye Ran Kim, Jungsoo Lee, Howard Chu, Kyoung Yong Jeong, Kyung Hee Park, Jung Dong Kim, Hong Kee Kim, Do Hyeon Jeong, Tai-Soon Yong, Jung-Won Park, Kwang Hoon Lee
Allergen-specific immunotherapy (SIT) is an effective treatment modality for allergic diseases such as atopic dermatitis (AD). However, frequent visits over a 3-year period as well as looming adverse events tend to discourage patient compliance. Therefore, a more convenient, effective, and safe method of SIT is needed. For several decades, use of microneedles has been promoted as an efficient and precise transdermal drug delivery method. In this study, we developed Dermatophagoides farinae (D. farinae) extract (DfE)-loaded microneedle patches, and evaluated their safety and efficacy as a novel SIT method...
October 4, 2017: Biomaterials
keyword
keyword
54047
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"